Switching to Ziprasidone for Schizophrenia or Schizoaffective Disorder
About this title
Read the official source — NCT01198353This study evaluated the effectiveness of Ziprasidone for people with schizophrenia.
Understand this study
What did researchers investigate?
This study evaluated the effectiveness of Ziprasidone for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Ansan and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 67
- Sponsor
- Soonchunhyang University Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- South Korea
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT01198353
- Official title
Show the full official title
Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients With Schizophrenia or Schizoaffective Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Ansan · Bucheon-si · Incheon
1 more locations
- Seoul
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the effectiveness of Ziprasidone for people with schizophrenia.
Who is behind this study?
The study sponsor is Soonchunhyang University Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Ziprasidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
